Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
BACKGROUND
Sorafenib is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma (HCC), setting a new standard for first-line treatment. However, no one has yet been able to predict sensitivity to sorafenib. Pre-treatment pERK level has been shown to be associated with favorable response to such therapy in a phase II clinical study, indicating that pERK may be a potential biomarker for treatment of HCC with sorafenib.


METHODS
The effects of sorafenib and 5-fluorouracil (5-FU) on cell proliferation were evaluated by cell viability assays in four HCC cell lines (SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6) with different metastatic potential and basal pERK expression levels. Expression levels of pERK were determined by immunocytochemical quantification together with western blot analysis, and pERK density values were also calculated. Correlation analyses were then carried out between the IC50 values of drugs and pERK density values. After basal ERK phosphorylation was down-regulated with U0126 in MHCC97-H cells, cellular responsiveness to sorafenib was assessed by cell viability assay.


RESULTS
Basal pERK levels increased stepwise in cell lines in accordance with their metastatic potential. Sorafenib inhibited ERK phosphorylation in a dose-dependent manner in all four cell lines at a concentration between 5 and 20 microM, but the degree of inhibition was significantly different according to their basal pERK expression level (P < 0.0001). In contrast, no significant change was observed after 5-FU treatment. Correlation analyses between the IC50 values and pERK densities revealed that the effects of sorafenib on cell proliferation were significantly correlated with basal pERK levels (Spearman r = -0.8671, P = 0.0003). Resistance to 5-FU was also significantly associated with basal pERK expression in these HCC cell lines (Spearman r = 0.7832, P = 0.0026). After the basal ERK phosphorylation level in MHCC97-H cells was reduced with U0126, they were significantly less sensitive to sorafenib-mediated growth inhibition, with an IC50 of 17.31 +/- 1.62 microM versus 10.81 +/- 1.24 microM (P = 0.0281).


CONCLUSIONS
In this in vitro study, pERK was confirmed to be a potential biomarker predictive of sensitivity to sorafenib in treating HCC. The RAF/MEK/ERK pathway may be involved in drug resistance to traditional chemotherapy in HCC.
Zhang
Zhe
Z
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, PR China. zhangzhe2006@hotmail.com
Zhou
Xiaoyun
X
Shen
Hujia
H
Wang
Dexing
D
Wang
Yanhong
Y
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000494:pharmacology*; D015415:Biomarkers; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival; D004351:Drug Resistance; D048049:Extracellular Signal-Regulated MAP Kinases / Q000032:analysis*; D022781:Hepatocytes / Q000737:chemistry*; D006801:Humans; D007120:Immunochemistry / Q000379:methods; D020128:Inhibitory Concentration 50; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D015415:Biomarkers; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D048049:Extracellular Signal-Regulated MAP Kinases
Cancer Res. 2001 May 1;61(9):3640-6
11325833
Cancer Metastasis Rev. 2003 Dec;22(4):395-403
12884914
Cancer Res. 2006 Dec 15;66(24):11851-8
17178882
Adv Enzyme Regul. 2006;46:249-79
16854453
J Cancer Res Clin Oncol. 2004 Aug;130(8):460-8
15146329
J Hepatol. 2004 Nov;41(5):864-80
15519663
J Clin Oncol. 2006 Sep 10;24(26):4293-300
16908937
Hepatol Res. 2004 Jun;29(2):113-121
15163433
Hepatology. 2005 Nov;42(5):1208-36
16250051
Cancer Res. 2004 Oct 1;64(19):7099-109
15466206
Lancet. 2003 Dec 6;362(9399):1907-17
14667750
Cancer Biol Ther. 2007 Sep;6(9):1461-8
18424914
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Nat Rev Cancer. 2003 Jan;3(1):11-22
12509763
Br J Cancer. 1999 Nov;81(5):814-21
10555751
Hepatology. 2003 Feb;37(2):429-42
12540794
Oncogene. 2007 May 14;26(22):3291-310
17496923
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Clin Oncol. 2008 Jun 1;26(16):2707-16
18509183